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OBJECTIVE—Chronic exercise and obesity both increase intra-
myocellular triglycerides (IMTGs) despite having opposing effects
on insulin sensitivity. We hypothesized that chronically exercise-
trained muscle would be characterized by lower skeletal muscle
diacylglycerols (DAGs) and ceramides despite higher IMTGs and
would account for its higher insulin sensitivity. We also hypothe-
sized that the expression of key skeletal muscle proteins involved in
lipid droplet hydrolysis, DAG formation, and fatty-acid partitioning
and oxidation would be associated with the lipotoxic phenotype.
RESEARCH DESIGN AND METHODS—A total of 14 normal-
weight, endurance-trained athletes (NWA group) and 7 normal-
weight sedentary (NWS group) and 21 obese sedentary (OBS
group) volunteers were studied. Insulin sensitivity was assessed
by glucose clamps. IMTGs, DAGs, ceramides, and protein expres-
sion were measured in muscle biopsies.
RESULTS—DAG content in the NWA group was approximately
twofold higher than in the OBS group and ~50% higher than in the
NWS group, corresponding to higher insulin sensitivity. While
certain DAG moieties clearly were associated with better insulin
sensitivity, other species were not. Ceramide content was higher
in insulin-resistant obese muscle. The expression of OXPAT/
perilipin-5, adipose triglyceride lipase, and stearoyl-CoA desatur-
ase protein was higher in the NWA group, corresponding to a
higher mitochondrial content, proportion of type 1 myocytes,
IMTGs, DAGs, and insulin sensitivity.
CONCLUSIONS—Total myocellular DAGs were markedly higher
in highly trained athletes, corresponding with higher insulin sen-
sitivity, and suggest a more complex role for DAGs in insulin action.
Our data also provide additional evidence in humans linking
ceramides to insulin resistance. Finally, this study provides novel
evidence supporting a role for speciﬁc skeletal muscle proteins
involved in intramyocellular lipids, mitochondrial oxidative capac-
ity, and insulin resistance. Diabetes 60:2588–2597, 2011
Skeletal muscle insulin resistance (IR) is associ-ated with obesity and physical inactivity and iscrucial for the development of type 2 diabetes (1).Unfortunately, the causes of IR within muscle are
not known. Concerted efforts have been made over the past
several years to understand the potential role of intra-
myocellular lipid (IMCL) accumulation in the development
of IR (2). Studies in both animal models (3) and humans (4)
provided early evidence that IMCLs, such as triglycerides,
were associated with skeletal muscle IR. However, we sub-
sequently reported on the athletes paradox in which chron-
ically exercised humans were markedly insulin-sensitive
despite having high intramyocellular triglycerides (IMTGs)
(5), a phenomenon corroborated by others (6). These
observations gave pause to the widely held view that
IMCLs cause IR within the muscle and lent support to the
concept that other potentially damaging IMCLs may play
a role in the development of IR.
Diacylglycerols (DAGs) and ceramides are lipid inter-
mediates widely believed to be the true lipotoxic culprits
underlying the reported associations between muscle tri-
glycerides and IR, thereby explaining the athletes paradox
and the root cause of muscle IR. Indeed, several lines of
evidence from cell systems and animal models indicate
that elevated DAGs (7) or ceramides (8) are associated
with impaired insulin signaling and IR. Previous studies
examining skeletal muscle DAG and ceramide content re-
lated to human IR, however, are limited and inconsistent
(9,10). Because it has become clear that chronic exercise
training increases IMTGs (5,11), recent studies have been
conducted to examine whether both DAGs and ceramides
are reduced with exercise (12–14). Another prevalent no-
tion is that higher mitochondria content and capacity for
fatty acid oxidation caused by exercise training are re-
sponsible for lower DAG and ceramide content (15). We
recently have shown that exercise training does indeed
decrease these IMCLs in conjunction with increased oxi-
dative capacity and improved insulin sensitivity (12). The
distinct roles that chronic exercise and obesity may play in
the link between these potentially harmful lipid species and
skeletal muscle IR, however, remain to be elucidated.
Moreover, it is not known whether speciﬁc molecular
species of these complex lipids are associated with
skeletal muscle IR according to their fatty acid chain
length or degree of saturation. Therefore, we used mass
spectrometry to quantify the content and molecular spe-
cies proﬁle of both DAGs and sphingolipids within skel-
etal muscle biopsies in human subjects widely disparate
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for physical activity and obesity to test the following
primary hypothesis: endurance-trained athletes, despite
having higher IMTGs, would have the lowest muscular
DAG and ceramide content, the highest insulin sensitivity,
and the highest mitochondrial content compared with both
normal weight and obese sedentary subjects and that these
differences would be more pronounced for saturated DAG
and ceramide species. In addition, we investigated several
proteins associated with lipid droplet esteriﬁcation and lipol-
ysis: oxidative perilipin adipophilin TIP47 (OXPAT)/perilipin-5
or lipid storage protein 5 because of its reported role in
lipid droplet formation and enhanced fatty acid oxidation
(16,17); the lipogenic enzymes stearoyl-CoA desaturase 1
(SCD1) and diacylglycerol acyltransferase 1 (DGAT1); and
adipose triglyceride lipase (ATGL). These data provide
novel insight into the role of lipid-induced IR within human
skeletal muscle.
RESEARCH DESIGN AND METHODS
A total of 42 older (aged 66.26 0.7 years [range 60–75]) volunteers were recruited
and classiﬁed as obese (BMI .30 kg/m2) and sedentary (OBS group; n = 21),
normal weight (BMI 18–25 kg/m2) and sedentary (NWS group; n = 7), and normal
weight and endurance trained (NWA group; n = 14). Sedentary was deﬁned as
#1 day per week of a structured exercise session of,20 min. Endurance trained
was deﬁned as ﬁve or more structured aerobic exercise sessions per week.
Subjects were in good general health, nonsmokers, and weight stable
(63 kg) for at least 6 months. Fasting lipid proﬁle, electrolytes, plasma glu-
cose, complete blood count, platelet count, HbA1c, kidney function, thyroid-
stimulating hormone, and liver function were determined. A standard 75-g oral
glucose tolerance test (OGTT) was performed. Potential subjects were ex-
cluded if they had fasting glycemia $126 or $200 mg/dL after a 2-h OGTT,
hematocrit level,34%, or a thyroid-stimulating hormone level.8 mIU/mL or if
they were taking chronic medication known to affect glucose homeostasis.
The University of Pittsburgh Institutional Review Board approved the pro-
tocol. All volunteers gave written consent.
Body composition. Total body fat mass and lean body mass (LBM) were
measured by dual-emission X-ray absorptiometry (Lunar Prodigy; GE Health-
care, Milwaukee, MI). Visceral (VAT), subcutaneous (SAT), and total (TAT)
abdominal adipose tissue were measured from a single slice (L3–L4 level) by
magnetic resonance imaging (Siemens 3T Trio; Medicals Systems, Erlangen,
Germany) or computed tomography (9800 CT scanner; GE Healthcare) (2,18).
To account for possible differences in the two imaging methods, the following
ratios were computed: VAT-to-TAT, SAT-to-TAT, and VAT-to-SAT.
Physical ﬁtness. VO2 peak was measured with a graded exercise protocol on
an electronically braked cycle ergometer (Ergoline 800S; Sensormedics, Yorba
Linda, CA) with indirect calorimetry (Moxus, AEI Technologies, Pittsburgh,
PA), as described previously (11).
Insulin sensitivity. Insulin sensitivity was measured as the rate of insulin-
stimulated glucose disposal (Rd) during a 4-h hyperinsulinemic-euglycemic
clamp (40 mU/m2/min) coupled with stable isotope tracer dilution, as de-
scribed previously (5). Subjects were instructed not to perform physical ex-
ercise 48 h before the clamp to avoid the acute effects of exercise on insulin
sensitivity. Indirect calorimetry (Parvomedics TrueOne, Sandy, UT) was used
during the clamp to calculate oxidative and nonoxidative glucose disposal.
Muscle biopsy. Percutaneous muscle biopsies were performed before the
clamp, following the same standardized conditions as described above. Bi-
opsies were obtained from the vastus lateralis as described previously (19).
After trimming of visible adipose tissue with a dissecting microscope (Leica
EZ4; Leica Microsystems, Wetzlar, Germany), two portions of the specimen
(~30 mg each) were ﬂash-frozen in liquid nitrogen and stored at 280°C for
Western blotting and for ceramide and DAG analysis. A third portion was used
for histochemical analysis. A fourth portion (~5 mg) was used for transmission
electron microscopy. All analyses were then performed in a blind manner.
Histochemistry. Histochemical analysis was performed on serial sections
using methods previously described (11,12). IMTG content was determined by
the Oil Red O (ORO). To quantify ﬁber-speciﬁc IMTGs, the sections were
costained with ORO and human myosin heavy-chain MYH7 (type I) and MYH2
(type IIa) (all antibodies from Santa Cruz Biotechnology, Santa Cruz, CA).
Succinate dehydrogenase (SDH) staining was used as a marker for oxidative
capacity. Images were visualized using a Leica microscope (DM4000B; Leica
Microsystems) and digitally captured (Retiga 2000R; Q Imaging, Surrey, BC,
Canada), and semiquantitative image analysis was performed (Northern
Eclipse; Empix Imaging, Cheektowaga, NY). All units for the histology are in
average gray and reported as arbitrary units (AUs). The proportion of type I,
type IIa, and type IIx was computed from ~150 to 300 ﬁbers per subject. The
interassay variability for the ﬁber type–speciﬁc ORO measure assessed on
three subjects was ,6%.
Analysis of DAGs, ceramides, and sphingolipids. Quantiﬁcation of in-
tramuscular DAGs, ceramides, and sphingolipids was performed using high-
performance liquid chromatography–tandem mass spectrometry, as described
previously (20). Tissue homogenates were fortiﬁed with internal standards
and extracted into a one-phase neutral organic solvent system (ethyl acetate/
isopropyl alcohol/water; 60:30:10 vol/vol/vol), evaporated and reconstituted
in methanol, and analyzed by a surveyor/TSQ 7000 LC/MS System (Thermo
Electron Finnigan; Thermo Fisher Scientiﬁc, Waltham, MA) (21). Quantitative
analysis was performed in a positive multiple-reaction–monitoring mode, based
on calibration curves generated by adding to an artiﬁcial matrix known amounts
of target analytes, synthetic standards, and an equal amount of internal standard.
The DAG and ceramide levels were normalized to total protein levels.
Protein expression. Frozen tissue was homogenized in ice-cold cell lysis
buffer (Cell Signaling Technology, Danvers, MA) with protease inhibitor
cocktail tablets (Roche Diagnostics, Mannheim, Germany). Protein content was
determined in triplicate with a bicinchoninic acid assay (ThermoScientiﬁc,
Rockford, IL). The homogenates were mixed with 53 Laemmli buffer and
heated for 5 min at 95°C. The samples were loaded in equal amounts of protein
and resolved in a 12% SDS-PAGE followed by transfer onto polyvinylidene
diﬂuoride membranes (Bio-Rad Laboratories, Hercules, CA). After blocking,
membranes were probed overnight at 4°C with the anti-myocardial lipid droplet
protein (MLDP) (OXPAT/perilipin-5) antibody (American Research Products,
Belmont, MA), anti-SCD1 (Alpha Diagnostic International, San Antonio, TX),
anti-DGAT1 (Novus Biologicals, Littleton, CO), and anti-ATGL (Cell Signaling,
Boston, MA). Blots were normalized to either anti–b-actin (Santa Cruz Bio-
technology, Santa Cruz, CA). A prestained molecular-mass marker (10–170
kDa) was used to determine protein size (Fermentas International, Burlington,
Ontario, Canada). Immunoreactive proteins were detected by chemiluminescence
(Bio-Rad Laboratories) using appropriate horseradish peroxidase–conjugated
secondary antibodies. Speciﬁc bands were quantiﬁed by densitometry using the
software ImageJ (National Institutes of Health, Bethesda, MD). To reduce bias,
all samples were loaded on the same day, and all gels and membranes were
processed at the exact same time with the same solutions.
Transmission electron microscopy. Transmission electron microscopy anal-
ysis was conducted in batches, as described previously (22). Approximately
18–20 micrographs were obtained from randomly sampled transverse sec-
tions of muscle ﬁbers and were acquired (JEM-1210; Jeol, Tokyo, Japan) at
336,000 magniﬁcation using stereological analysis with digital-imaging software
(Metamorph 6.3; Molecular Devices, Sunnyvale, CA) .
Statistical analysis. Data are presented as means 6 SEM. After checking
normality with the Shapiro-Wilk test and equality of variance with the Levene
test, one-way ANOVAs were performed to examine group differences. Post
hoc tests were performed with the Tukey-Kramer honestly signiﬁcant adjust-
ment. If assumptions were not met, comparisons between groups were per-
formed with the Welch adaptation to the ANOVA test. Pairwise correlations
were performed with the Spearman r correlation.
To identify patterns of distribution and reduce the dimensionality of the
data, while retaining as much of the variance as possible, a principal component
analysis (PCA) of the individual moieties of DAGs (13 subspecies) and ceramides
(8 subspecies) was performed. PCA was used as exploratory data analysis to
convert a set of possibly correlated variables into a set of data of uncorrelated
variables called principal components or factors, thus revealing the internal
structure of the data in a way that best explains the variance of the data. After
inspecting the correlation matrix, factors were identiﬁed on the basis of the
strength of the loading; thus the ﬁrst factor had as high a variance as possible, and
each succeeding factor had the highest variance possible under the constraint
that it be uncorrelatedwith the preceding factor. For each factor, Cronbachawas
computed to assess the degree of homogeneity among the indicators. To assess
the physiological relevance of PCA ﬁndings, we combined the indictors loading
on each PCA factor by summing the different species scores within each factor
and then performed one-way ANOVAs of these combined scores to compare
groups. The a level was set a priori to 0.05. Statistical analyses were performed
using JMP 5.0.1.2 and SPSS version 16.0 for the Macintosh.
RESULTS
Subject characteristics, body composition, and physical
ﬁtness. Subject characteristics are presented in Table 1.
OBS subjects had higher BMI and more body fat than
both the NWA and the NWS subjects. VO2 peak was .50%
higher in NWA subjects compared with both NWS and
OBS subjects.
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Insulin sensitivity and metabolic variables. Peripheral
insulin sensitivity was higher in NWA subjects compared
with NWS subjects, who in turn were more insulin-sensitive
than the OBS subjects (Table 2). These differences were
explained by differences in nonoxidative glucose disposal
(P , 0.01) but not in oxidative glucose disposal (P =
0.25). These differences remained after adjusting for the
higher VAT in the obese subjects. Hepatic insulin sensi-
tivity was lower in OBS compared with NWA and NWS
subjects.
OBS subjects had higher fasting and 2-h blood glucose
levels, along with higher fasting insulin levels, reﬂecting
their overall worse metabolic proﬁle (Table 2). Total and
LDL cholesterols were similar across groups, although it is
important to note that the proportion of subjects who were
taking lipid-lowering medication was signiﬁcantly different
across the three groups as follows: 0% in the NWA group,
29% in the NWS group, and 38% in the OBS group. HDL
cholesterol and plasma triglycerides, however, were both
more favorable in NWA and NWS subjects.
IMTG and lipid droplet volume density. Total-muscle
IMTG content, measured by ORO staining and electron
microscopy, was higher in NWA and OBS subjects com-
pared with NWS subjects (P = 0.024) (Fig. 1). These dif-
ferences were consistent for type I and type IIa myoﬁbers.
Neither IMTG measured by the ORO staining nor lipid
droplet density was correlated with insulin sensitivity (r =
20.008 and r = 20.25, respectively, both P . 0.05).
Skeletal muscle DAGs. Total DAG content was ~50%
higher (P , 0.01) in the skeletal muscle of NWA compared
with NWS subjects and approximately twofold higher in
NWA compared with OBS subjects (Fig. 2). Similar dif-
ferences were observed for saturated DAGs (P, 0.01) and
for DAG species in which one of the fatty acids was un-
saturated (P , 0.01). In contrast, OBS subjects had ele-
vated DAG species that contained an unsaturated fatty
acid on both positions compared with both NWS and NWA
subjects (P , 0.01). These disparate results also are evi-
dent across the individual DAG species shown in Fig. 2.
PCA identiﬁed three factors that combined to explain
89.1% of the total variance in DAGs (Table 3). When the
species belonging to factor 1 were summed and compared
across groups, NWA subjects had a higher (P , 0.01)
content (1,774 6 118 pmol/mg protein) than both NWS
(1,203 6 167) and OBS (807.9 6 112.4) subjects. When the
species of factor 2 were summed, OBS subjects had a
higher (P = 0.046) content (17.86 2.3) than NWS (7.66 3.4)
subjects; NWA subjects were not different (12.26 2.4) from
the OBS subjects or from NWS subjects. The sum of the
components of factor 3 was higher in OBS subjects than in
TABLE 1
Subjects’ characteristics, body composition, and physical ﬁtness
Athletes Normal-weight subjects Obese subjects
n 14 7 21
Sex (male/female) 10/4 3/4 11/10
Age (years) 65.1 6 1.3 66.5 6 1.8 66.8 6 1.0
Weight (kg) 68.1 6 2.4B 70.4 6 3.4B 93.8 6 2.0A
BMI (kg/m2) 23.7 6 0.6B 24.5 6 0.9B 32.9 6 0.5A
Waist circumference (cm) 79.5 6 2.3B 85.5 6 3.9B 109.7 6 2.2A
LBM (kg) 51.5 6 2.5 43.4 6 3.5 51.1 6 2.0
Fat mass (kg) 13.9 6 1.9A 23.7 6 2.6B 38.8 6 1.5C
Body fat (%) 20.3 6 2.4B 34.6 6 3.3A 41.9 6 1.9A
TAT (cm2) 223.6 6 32.4B 359.5 6 52.3B 592.3 6 26.8A
VAT (cm2) 68.3 6 15.0B 105.3 6 24.2B 204.8 6 12.4A
SAT (cm2) 155.3 6 26.9B 254.2 6 43.4B 374.8 6 22.3A
VO2 peak (L/min) 2.81 6 0.17
A 1.84 6 2.36B 1.71 6 1.36B
VO2 peak/LBM (mL/min/kg) 53.8 6 2.0
A 41.5 6 2.8B 33.3 6 1.6C
Data are means 6 SEM. A,B,CSigniﬁcant differences between groups (one-way ANOVA).
TABLE 2
Metabolic variables
Athletes Normal-weight subjects Obese subjects
n 14 7 21
Rd (mg/min/kg LBM) 12.31 6 0.55
A 9.74 6 0.77B 6.29 6 0.45C
HGP (%) 99.99 6 3.49A 99.61 6 4.75A 85.87 6 2.74B
Fasting blood glucose (mmol/L) 4.84 6 0.17B 4.56 6 0.25B 5.31 6 0.12A
HbA1c (%) 5.40 6 0.12
B 5.61 6 0.18AB 5.84 6 0.10A
Fasting insulin (pmol/L) 17.91 6 4.70B 18.68 6 6.42B 45.08 6 3.70A
Glucose 2-h OGTT (mmol/L) 6.35 6 0.44B 6.75 6 0.64B 8.26 6 0.37A
Total cholesterol (mmol/L) 4.82 6 0.18 4.67 6 0.26 4.96 6 0.15
HDL (mmol/L) 1.67 6 0.09A 1.43 6 0.12AB 1.33 6 0.07B
LDL (mmol/L) 2.83 6 0.15 2.86 6 0.21 3.04 6 0.12
VLDL (mmol/L) 0.33 6 0.04B 0.37 6 0.06B 0.59 6 0.04A
Triglycerides (mmol/L) 0.88 6 0.12B 1.03 6 0.17B 1.62 6 0.10A
Data are means 6 SEM. HGP, hepatic insulin sensitivity expressed as the suppression of hepatic glucose production. Rd, whole-body insulin
sensitivity expressed as the rate of insulin-simulated glucose disposal. A,B,CSigniﬁcant differences between groups (one-way ANOVA).
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the NWS and NWA subjects (82.1 6 15.6, 19.1 6 23.6, and
32.1 6 16.7, respectively, P = 0.036). Total DAGs was
positively correlated with insulin sensitivity (r = 0.57, P ,
0.05). This positive association was similar for the sum of
the species of factor 1 (r = 0.57, P , 0.05). Factors 2 and 3,
however, were not correlated with insulin sensitivity (r =
20.21 and r = 20.17, respectively, P . 0.05).
Skeletal muscle ceramides and other sphingolipids.
Total ceramide content was higher (P , 0.01) in the
skeletal muscle of OBS subjects compared with both NWS
and NWA subjects (Fig. 3). These differences were consis-
tent across both saturated (P = 0.03) and unsaturated (P ,
0.01) ceramide species, as well as fatty acid chain length.
Sphingosine-1-phosphate (S1P) also was higher in obesity
(Fig. 3). In contrast, sphingosine was signiﬁcantly lower in
OBS compared with both NWA and NWS subjects.
PCA identiﬁed four signiﬁcant factors, explaining 87.2%
of the total variance in ceramides (Table 3). When the
molecular species belonging to factor 1 were summed and
compared across groups, OBS subjects were found to have
a higher (P = 0.02) content (159.6 6 18.4 pmol/mg protein)
than NWS (80.2 6 27.1) and NWA (82.8 6 21.0) subjects.
The same pattern was found for factor 2, with a higher
content in OBS (13.7 6 1.7) than NWS (7.1 6 2.4) and
NWA (6.2 6 1.9, P = 0.03) subjects. The component of
factor 3 revealed no differences (P = 0.28) across the
groups, whereas component factor 4 was signiﬁcantly (P =
0.04) higher in NWA (1.99 6 0.27) and NWS (1.87 6 0.35)
compared with OBS (1.10 6 0.24) subjects. Total ceramide
content was negatively correlated with insulin sensitivity
(r = 20.48, P , 0.05). Similar associations were observed
for saturated ceramide and unsaturated ceramide (r = 0.44
and r = 0.50, respectively, P , 0.05). When the sum of the
species belonging to the PCA factors were correlated to
insulin sensitivity, factors 1 and 2 were signiﬁcantly neg-
atively correlated with insulin sensitivity (r = 20.46 and
r = 20.47, respectively, P , 0.05), whereas factor 4 was
positively correlated (r = 0.38, P , 0.05) and factor 3 was
not signiﬁcantly correlated (r = 20.08, P . 0.05) with in-
sulin sensitivity.
Mitochondria, oxidative capacity, and proportion of
skeletal muscle ﬁber types. Mitochondria volume den-
sity was signiﬁcantly higher in NWA than in the two sed-
entary groups (P , 0.001) (Fig. 4A). SDH content was
higher in NWA than NWS subjects, who in turn had higher
SDH than OBS subjects (P , 0.001) (Fig. 4B). Mitochon-
dria volume density and SDH content were positively
correlated with insulin sensitivity (r = 0.51 and r = 0.67,
respectively, all P , 0.05).
NWA subjects had a higher (P, 0.01) proportion of type 1
myoﬁbers (70.2 6 4.2%) compared with NWS (34.4 6 4.0%)
and OBS (43.7 6 2.1%) subjects and a correspondingly
lower proportion of type 2 ﬁbers. The proportion of type I
ﬁbers was positively correlated with insulin sensitivity (r =
0.56, P . 0.05), whereas the proportion of type IIa and IIx
ﬁbers was negatively correlated with insulin sensitivity (r =
20.39 and r = 20.59, respectively, P , 0.05).
Lipid droplet protein content. NWA subjects had sig-
niﬁcantly more OXPAT/perilipin-5, SCD1, and ATGL than
the two sedentary groups (all P , 0.05) (Fig. 5). No dif-
ferences between groups were observed for DGAT1. There
was notably more variability in OXPAT/perilipin-5 ex-
pression, as indicated by the larger error bars, although
this greater variation is not adequately depicted in the
representative bands for this protein. This was likely a re-
sult of the greater biological variability. OXPAT/perilipin-5
content was positively correlated with insulin sensitivity
(r = 0.52, P , 0.01) and lipid droplet volume density (r =
0.45, P , 0.05). SCD1 was positively correlated with in-
sulin sensitivity (r = 0.58, P , 0.01) and with lipid droplet
volume density (r = 0.33, P , 0.01). ATGL was positively
correlated with insulin sensitivity (r = 20.48, P, 0.01) but
not with lipid droplet density (r = 0.28, P = 0.25). DGAT1
was not signiﬁcantly correlated with BMI, insulin sensi-
tivity, or lipid droplet density.
DISCUSSION
A primary ﬁnding of our study was that DAG content
was approximately twofold higher within the highly
FIG. 1. IMCLs and lipid droplet protein content in vastus lateralis.
IMTG measured by the ORO stain (A) and lipid droplet volume density
measured by electron microscopy (B). Bars are mean values and error
bars are SEMs. The letters A and B above the bars denote signiﬁcant
differences between groups (P < 0.05, one-way ANOVA).
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insulin-sensitive skeletal muscle compared with obese skel-
etal muscle. This clearly does not support a common con-
temporary view, largely based on evidence from animal
models, that muscular DAGs explain IR of obesity, aging,
and type 2 diabetes (23). To the contrary, our data suggest
that higher DAG content in chronically exercised, insulin-
sensitive muscle represents another athletes paradox (i.e.,
total cellular DAG content is associated with better insulin
sensitivity). These data are particularly signiﬁcant given
that few studies have examined skeletal muscle DAG con-
tent in association with IR, and still fewer studies have been
performed in human muscle (10,11,13,24). Our data also
are in accord with recent ﬁndings that DAGs are not ele-
vated in insulin-resistant muscle after controlling for obe-
sity and physical ﬁtness (24) and higher levels of DAGs in
lean subjects compared with obese volunteers (25), as well
as with an animal study indicating that increased DAG
content in muscle and IR are not necessarily related (26).
FIG. 2. DAGs in vastus lateralis. Total DAG content (A), saturated species (B), unsaturated species (C), and individual species (D). Bars are mean
values, and error bars are SEMs. The letters A, B, and C above the bars denote signiﬁcant differences between groups (P < 0.05, one-way ANOVA).
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Our results also differ somewhat from our previous report
demonstrating that moderate exercise reduced muscle DAG
content in previously sedentary obese subjects (12,27). It is
possible that these discrepancies are a result of the amount
and/or intensity of chronic exercise and the model system
used (acute lipid oversupply) or a result of subcellular DAG
location (i.e., membrane-bound or part of neutral lipid
droplets). It also is possible that particular DAG species
may differentially affect insulin action.
Ours is the ﬁrst study to provide a comprehensive proﬁle
of the distinct molecular species of DAG within muscle of
obese, normal-weight, and athletic human subjects, sug-
gesting that particular DAG species may be associated
with IR in muscle, whereas others clearly are not. This did
not seem to be related to the fatty acid chain length of the
DAG or the total degree of fatty acid saturation because
we found that exercised muscle had higher levels of both
saturated and unsaturated DAG species. It is difﬁcult to
reconcile our results with those in a recent study by
Bergman et al. (28), who found that the degree of satura-
tion of DAGs within muscle in athletes was lower com-
pared with sedentary subjects and was related to higher
insulin sensitivity. One possible explanation is that the
younger athletes in their study had a different diet com-
position. In addition, they measured the total fatty acid
content within the DAG pool, whereas we quantiﬁed spe-
ciﬁc DAG species. Our methods revealed that DAG species
containing one unsaturated and one saturated fatty acid
are lower in obese muscle but that DAG species containing
unsaturated fatty acids on both positions was higher in
obese muscle. The PCA supports this and suggests that it is
not the overall concentration of DAGs that is deleterious
but that particular DAG moieties may be lipotoxic even in
relatively smaller amounts. Additional studies are needed
to determine whether speciﬁc fatty acids stimulate DAG
synthesis and whether this is linked to IR.
Another key ﬁnding of our study was that ceramide
content was twofold higher in the obese muscle compared
with normal-weight sedentary and exercise-trained mus-
cles. These results are supported by previous studies in
human subjects reporting higher total ceramide levels in
obese muscle (8) and associations with IR and a lower
oxidative capacity (24,29). This also is in accord with our
previous report that moderate exercise training decreased
intramuscular ceramide levels in previously sedentary obese
subjects (12). Likewise, Bruce et al. (14) found that exer-
cise training tended to reduce both the total ceramide
content and the saturated ceramide species in obese insulin-
resistant subjects without signiﬁcant weight loss. In agree-
ment with Helge et al. (30), we did not ﬁnd signiﬁcant
differences between the athletes and normal-weight sed-
entary subjects with respect to total muscle content of
ceramides, which could be simply attributed to the levels
of ceramide required for normal physiological function.
Our results also are consistent with animal models and cell
systems linking ceramide content in muscle to impaired
insulin signaling and IR (31–33). Higher ceramide levels in
obesity and in association with IR were consistent for both
saturated and unsaturated ceramides, which is consistent
with our recent report (24). The PCA for ceramides sug-
gests, however, that a speciﬁc group of ceramides may be
related to better insulin sensitivity. Because ceramides have
several functions in normal biology, including comprising
mitochondria membranes (34), mechanistic investigations
are needed to examine the speciﬁc role of these ceramide
species on insulin action.
To our knowledge, this is the ﬁrst observation of higher
S1P in obese, insulin-resistant muscle. Among the bio-
active sphingolipids, ceramide, sphingosine, and S1P have
been proposed to exert differential effects on cells (35).
Ceramide is converted to sphingosine by the action of
ceramidases, and, subsequently, sphingosine is phosphor-
ylated to generate S1P (29,36). Ceramides and sphingosine
inhibit growth and are involved in apoptosis (37–39), in
contrast to the effects of S1P, which are to promote cellular
proliferation, survival, and inhibition of apoptosis (35).
Furthermore, S1P is implicated in the clearance of ceramide
(40), is a potential regulator of de novo ceramide synthesis
(41,42), and has been shown to inhibit Jun NH2-terminal
kinase activation (43). Samad et al. (44) reported a similar
observation in ob/ob mice, which had higher plasma levels
of total ceramide, sphingosine, and S1P compared with their
lean counterparts. Additional inquiry is needed to deter-
mine whether these speciﬁc sphingolipids actually affect
insulin action within muscle.
We also placed our novel lipid data within the context
of speciﬁc proteins associated with lipid droplet esteriﬁ-
cation, lipolysis, and oxidation. First, the lipid droplet pro-
tein OXPAT/perilipin-5, reported to be highly expressed in
highly oxidative tissues (16,45,46), was more than seven-
fold more abundant in the skeletal muscle of the endurance-
trained athletes, corresponding signiﬁcantly with their higher
lipid droplet volume and their higher insulin sensitivity.
One previous study in humans demonstrated no correlation
between OXPAT/perilipin-5 protein content in the skele-
tal muscle and insulin sensitivity in obese type 2 diabetic
subjects and BMI-matched control subjects (17). Our data
support a role for OXPAT/perilipin-5 in both higher lipid
droplet content and fatty acid oxidation, and, although our
observed associations with insulin sensitivity are intriguing,
additional studies are needed to determine whether it
directly mediates insulin action. Second, we investigated
two key lipogenic enzymes, SCD1 and DGAT1. SCD1 is
a rate-limiting enzyme that converts saturated fatty acids
to monounsaturated fatty acids and, in animal and cell
culture models, has been previously implicated in the
TABLE 3
Exploratory PCAs
Exploratory PCA on DAG species
Factor 1, eigenvalue 5.7 (43.6%)
Di-C16:0, C18:0/18:1, C16:0/18.1, C16:1/18:0, C16:0/18:0,
Di-C18:0, and Di-C18:1
Factor 2, eigenvalue 3.7 (28.4%)
Di-C16:1, Di-C14:0, and C14:0/18:0
Factor 3, eigenvalue 2.2 (17.1%)
C14:0/18:1, C14:0/16:0, and C16:1/18:1
Exploratory PCA on ceramides species
Factor 1, eigenvalue 3.3 (41.3%)
Lingoceric (C24:0), nervonic (C24:1), stearic (C18:0),
and arachidic (C20:0)
Factor 2, eigenvalue 1.3 (16.6%)
Dihydroceramide 16 and palmitoleic (C18:1)
Factor 3, eigenvalue 1.2 (15.1%)
Palmitic (C16:0)
Factor 4, eigenvalue 1.1 (14.3%)
Myristic (C14:0)
% refers to the percentage of variance of the data explained by each
factor.
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development of dysregulated fatty acid metabolism, in-
creased triglyceride storage, and obesity (47,48). In con-
trast, although conﬁrming that it tracks with higher muscle
triglycerides, our data in human muscle clearly demonstrate
that SCD1 is higher in metabolically healthy, more insulin-
sensitive muscle. This is in agreement with observations
of increases in SCD1 content after acute (49) and chronic
aerobic exercise training (27). The lack of differences in
DGAT between the groups is in accord with our previous
report (27). Third, we report elevated levels of ATGL
in endurance-trained athletes compared with sedentary
subjects. These data are supported by previous exercise-
training studies (50,51). ATGL is important as the ﬁrst
step in hydrolyzing triglycerides to DAG on its way to fur-
ther hydrolysis and ultimate energy generation, which could
explain the higher DAG levels in the muscle of the athletes.
Our interpretation of this ﬁnding is that these alterations in
esteriﬁcation and lipolysis within exercise-trained muscle
FIG. 3. Ceramides and other sphingolipids in vastus lateralis. Total, saturated, and unsaturated ceramide content (A), sphingosine and S1P (B),
and individual species of ceramides (C). Bars are mean rates, and error bars are SEMs. The letters A and B above the bars denote signiﬁcant
differences between groups (P < 0.05, one-way ANOVA).
INTRAMYOCELLULAR LIPIDS AND INSULIN RESISTANCE
2594 DIABETES, VOL. 60, OCTOBER 2011 diabetes.diabetesjournals.org
lead to an elevated pool of neutral DAGs, similar to that
of triglycerides that can be used as a fuel source during
physical activity. Taken together, these data suggest an
enzymatic proﬁle of enhanced neutral lipid storage and
oxidation associated with enhanced insulin sensitivity with
exercise training.
These human studies cannot directly determine mech-
anisms or causes of IR. Although we did not determine
whether IMCLs are associated with speciﬁc defects in
insulin signaling, we clearly show that insulin-stimulated
glucose disposal in skeletal muscle differed according to
study groups. Additional studies are needed to examine
whether the speciﬁc lipid species or their cellular location,
in particular DAG within muscle, are mechanistically linked
with impaired insulin signaling. It will also be important to
determine whether the fatty acid composition of the diet
affects insulin action within muscle because dietary patterns
have been shown to inﬂuence lipid metabolite content and
saturation (3). We did not measure other intracellular lipids
that have been implicated in muscle IR, such as long-chain
fatty acyl-CoA (52,53) because of the limited availability of
tissue within the relatively small biopsy samples. Another
important element to consider is that the amount and
intensity of physical activity performed by these highly
trained athletes do not allow us to extrapolate these
ﬁndings in athletes to more moderate physical activity as
emphasized for general health. Thus, the possibility remains
that there is some threshold level or dose-response effect of
physical activity on insulin sensitivity and these lipids.
In summary, high-level exercise training was unex-
pectedly associated with considerably higher total DAG
content within skeletal muscle concomitant with higher
insulin sensitivity, thus extending the athletes paradox to
muscle DAGs and to triglycerides across ﬁber types.
Therefore, the total cellular DAG content cannot explain
skeletal muscle IR. This suggests instead a role for speciﬁc
molecular species of DAGs and possibly their subcellular
location in this metabolic abnormality. Ceramides and S1P,
on the other hand, are consistently elevated in obese and
insulin-resistant muscle. Moreover, formation and metabolism
FIG. 4. Mitochondria and markers of oxidative capacity in vastus lateralis. Mitochondria volume density (A), example of micrographs (B), and SDH
content (C). Bars are mean values, and error bars are SEMs. The letters A, B, and C above the bars denote signiﬁcant differences between groups
(P < 0.05, one-way ANOVA).
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of these complex lipids were associated with key pro-
teins expressed in human muscle, which in turn corre-
sponded signiﬁcantly with IR. These novel translational
data form a basis for more mechanistic studies to be per-
formed in model systems to determine exact causes of lipid-
induced IR.
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